WuXi Biologics (Cayman) (WXXWY) Stock Price, News & Analysis

Company Overview

WuXi Biologics (Cayman) Inc., trading OTC as WXXWY, is a global contract research, development and manufacturing organization (CDMO) specializing in biologics. Founded as a spin-out from WuXi AppTec and incorporated in the Cayman Islands in 2017, the company offers end-to-end support across the biologics value chain. Its service portfolio encompasses discovery biology, analytical development, process chemistry and large-scale manufacturing for therapeutic proteins and antibodies.

The firm’s core offerings include the development of monoclonal antibodies, recombinant proteins and cell and gene therapy vectors. WuXi Biologics operates multiple cGMP facilities in China, the United States, Europe and Asia-Pacific, enabling seamless technology transfer and consistent production across geographies. Analytical and quality control services, such as bioassays, chromatography and biosafety testing, further underpin its integrated CDMO platform.

Since its Hong Kong Stock Exchange listing in June 2017, WuXi Biologics has expanded its global footprint through strategic capacity additions and partnerships with biopharmaceutical innovators. The company’s network includes manufacturing sites in Shanghai, Wuxi, Madison (Wisconsin), and European campuses in Germany and Ireland, as well as process development centers in Singapore and the U.S.

Under the leadership of Chairman and CEO Dr. Chris Chen, WuXi Biologics emphasizes innovation and technology transfer to accelerate biologics development. The management team comprises industry veterans with deep expertise in biologics R&D, regulatory affairs and large-scale manufacturing. Through its integrated platform, the company aims to streamline the path from candidate selection to commercial supply for its global clientele.

Key Stats

• Today's Range: $7.70 to $7.98
• 50-Day Range: $7.78 to $9.60
• 52-Week Range: $6.02 to $11.21
• Volume: 94,483 shs
• Average Volume: 75,446 shs
• Market Capitalization: $16.10 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Company Calendar

• Today: 6/09/2026
• Next Earnings (Estimated): 8/26/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:WXXWY
• CIK: N/A
• Web: www.wuxibiologics.com.cn
• Phone: 8651081831205
• Fax: N/A
• Employees: 12,435
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,068,897,000
• Free Float: N/A
• Market Cap: $16.10 billion
• Optionable: Not Optionable
• Beta: N/A